Cryder Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $210M | Buy |
419,181
+42,500
| +11% | +$20.4M | 13.24% | 2 |
|
|
2026
Q1 | $185M | Hold |
376,681
| – | – | 12.09% | 3 |
|
|
2025
Q4 | $218M | Buy |
376,681
+32,005
| +9% | +$18.1M | 12.9% | 3 |
|
|
2025
Q3 | $167M | Hold |
344,676
| – | – | 9.23% | 6 |
|
|
2025
Q2 | $140M | Buy |
344,676
+19,875
| +6% | +$8.31M | 7.87% | 7 |
|
|
2025
Q1 | $162M | Hold |
324,801
| – | – | 12.1% | 4 |
|
|
2024
Q4 | $169M | Buy |
324,801
+34,448
| +12% | +$18.9M | 12.29% | 4 |
|
|
2024
Q3 | $180M | Hold |
290,353
| – | – | 10.35% | 6 |
|
|
2024
Q2 | $161M | Sell |
290,353
-132,309
| -31% | -$75.8M | 10.06% | 6 |
|
|
2024
Q1 | $246M | Buy |
422,662
+18,289
| +5% | +$10.3M | 10.68% | 6 |
|
|
2023
Q4 | $215M | Buy |
404,373
+12,283
| +3% | +$5.95M | 10.62% | 7 |
|
|
2023
Q3 | $198M | Sell |
392,090
-1,308
| -0.3% | -$697K | 9.59% | 7 |
|
|
2023
Q2 | $205M | Sell |
393,398
-1,283
| -0.3% | -$692K | 10.01% | 6 |
|
|
2023
Q1 | $227M | Hold |
394,681
| – | – | 12.1% | 3 |
|
|
2022
Q4 | $217M | Sell |
394,681
-37,847
| -9% | -$20.1M | 13.44% | 2 |
|
|
2022
Q3 | $219M | Sell |
432,528
-397
| -0.1% | -$222K | 13.61% | 1 |
|
|
2022
Q2 | $235M | Buy |
432,925
+30,608
| +8% | +$16.8M | 12.84% | 2 |
|
|
2022
Q1 | $238M | Buy |
402,317
+15,481
| +4% | +$8.89M | 11.68% | 5 |
|
|
2021
Q4 | $258M | Hold |
386,836
| – | – | 11.69% | 6 |
|
|
2021
Q3 | $221M | Buy |
386,836
+3,555
| +0.9% | +$1.95M | 11.03% | 6 |
|
|
2021
Q2 | $193M | Buy |
383,281
+84,694
| +28% | +$40M | 10.05% | 7 |
|
|
2021
Q1 | $136M | Buy |
298,587
+6,398
| +2% | +$3.05M | 9.74% | 7 |
|
|
2020
Q4 | $136M | Sell |
292,189
-62,130
| -18% | -$29.1M | 10.87% | 6 |
|
|
2020
Q3 | $156M | Hold |
354,319
| – | – | 14.54% | 1 |
|
|
2020
Q2 | $128M | Hold |
354,319
| – | – | 13.91% | 2 |
|
|
2020
Q1 | $100M | Sell |
354,319
-43,861
| -11% | -$13.8M | 14.65% | 2 |
|
|
2019
Q4 | $129M | Sell |
398,180
-15,908
| -4% | -$4.82M | 14.67% | 2 |
|
|
2019
Q3 | $121M | Buy |
414,088
+13,438
| +3% | +$3.85M | 15.49% | 1 |
|
|
2019
Q2 | $118M | Hold |
400,650
| – | – | 17.4% | 1 |
|
|
2019
Q1 | $110M | Buy |
400,650
+3,096
| +0.8% | +$770K | 16.86% | 2 |
|
|
2018
Q4 | $89M | Sell |
397,554
-11,681
| -3% | -$2.74M | 16.19% | 1 |
|
|
2018
Q3 | $99.9M | Buy |
409,235
+592
| +0.1% | +$136K | 15.37% | 2 |
|
|
2018
Q2 | $84.6M | Buy |
408,643
+161,130
| +65% | +$34.2M | 13.83% | 3 |
|
|
2018
Q1 | $51.1M | Buy |
247,513
+12,000
| +5% | +$2.52M | 14.68% | 3 |
|
|
2017
Q4 | $44.7M | Buy |
235,513
+42,153
| +22% | +$8.08M | 14.41% | 1 |
|
|
2017
Q3 | $36.6M | Hold |
193,360
| – | – | 14.94% | 2 |
|
|
2017
Q2 | $33.7M | Hold |
193,360
| – | – | 12.37% | 3 |
|
|
2017
Q1 | $29.7M | Buy |
193,360
+1,074
| +0.6% | +$164K | 12.04% | 4 |
|
|
2016
Q4 | $27.1M | Buy |
192,286
+27,582
| +17% | +$4.07M | 12.12% | 5 |
|
|
2016
Q3 | $26.2M | Buy |
164,704
+39,780
| +32% | +$6.13M | 15.36% | 1 |
|
|
2016
Q2 | $18.5M | Buy |
124,924
+12,013
| +11% | +$1.77M | 14.81% | 1 |
|
|
2016
Q1 | $16M | Buy |
112,911
+1,336
| +1% | +$179K | 12.23% | 5 |
|
|
2015
Q4 | $15.8M | Sell |
111,575
-24,883
| -18% | -$3.32M | 13.29% | 1 |
|
|
2015
Q3 | $16.7M | Buy |
136,458
+40,395
| +42% | +$5.26M | 10.78% | 3 |
|
|
2015
Q2 | $12.5M | Buy |
96,063
+2,595
| +3% | +$338K | 9.04% | 8 |
|
|
2015
Q1 | $12.6M | Buy |
+93,468
| New | +$12M | 8.84% | 7 |
|
Other funds holding TMO
N
Cryder Capital Partners's TMO Position: Q2 2026 in Review
Cryder Capital Partners increased its Thermo Fisher Scientific (TMO) stake by 11% in Q2 2026, buying an estimated $20.4M and bringing the position to 419,181 shares worth $210M. The position accounts for 13.24% of the portfolio, ranked #2.
Cryder Capital Partners first reported a position in TMO in Q1 2015 and has held it in 46 quarters since. The position peaked at $258M in Q4 2021. 1,759 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Cryder Capital Partners held 419,181 shares of Thermo Fisher Scientific worth $210M as of Q2 2026.
- Cryder Capital Partners bought 42,500 Thermo Fisher Scientific shares in Q2 2026, an estimated $20.4M.
- Thermo Fisher Scientific made up 13.24% of Cryder Capital Partners's portfolio in Q2 2026, its #2 holding.
- Cryder Capital Partners first reported a position in Thermo Fisher Scientific in Q1 2015 and has held it in 46 quarters since.
- Cryder Capital Partners's Thermo Fisher Scientific position peaked at $258M in Q4 2021.
- 1,759 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Cryder Capital Partners's 13F filing for Q2 2026, filed 4 Aug 2026.